Taking into account Chinese pharmaceutical procurement policies, the findings highlight the superior efficacy of NOACs, especially rivaroxaban, in enhancing both the quality of life and economic benefits for Chinese LVT patients. NOACs present a more cost-effective treatment option, improving patient quality of life and healthcare cost efficiency compared to warfarin.
Keyphrases
- oral anticoagulants
- atrial fibrillation
- healthcare
- left atrial
- left ventricular
- end stage renal disease
- venous thromboembolism
- pulmonary embolism
- heart failure
- direct oral anticoagulants
- newly diagnosed
- public health
- peritoneal dialysis
- prognostic factors
- acute myocardial infarction
- coronary artery disease
- aortic stenosis
- mitral valve